申请人:TAISHO PHARMACEUTICAL CO., LTD.
公开号:US20150141669A1
公开(公告)日:2015-05-21
Provided are a fluorine-containing amino acid prodrug represented by general formula (I) that makes a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, provided is a prodrug that increases the in vivo exposure and enhances the oral absorbability and other mucosal absorbability of a parent compound that acts on group 2 metabotropic glutamate receptors as an agent for the treatment or prevention of diseases in which group 2 metabotropic glutamate receptors are said to be involved, such as: schizophrenia, anxiety disorder and its related diseases, depression, bipolar disorder, epilepsy, developmental disorders, sleep disorders, and other neuropsychiatric diseases; and drug dependence, cognitive disorders, Alzheimer's disease, Huntington's chorea, Parkinson's disease, movement disorders associated with muscular rigidity, cerebral ischemia, cerebral insufficiency, spinal cord disorders, cephalopathy, and other neurological diseases.
提供了一种含
氟氨基酸前药,其通式表示为(I),可将作为2型代谢性谷
氨酸受体激动剂的含
氟氨基酸制成前药,或其药学上可接受的盐。更具体地,提供了一种前药,可增加在体暴露量并增强口服吸收和其他粘膜吸收,作为治疗或预防2型代谢性谷
氨酸受体参与的疾病的药物,如:精神分裂症,焦虑症及其相关疾病,抑郁症,双相障碍,癫痫,发育障碍,睡眠障碍和其他神经精神疾病;以及药物依赖,认知障碍,阿尔茨海默病,亨廷顿病,帕
金森病,与肌肉僵硬相关的运动障碍,脑缺血,脑血管不足,脊髓疾病,头痛和其他神经系统疾病。